Acute Lung Injury Global Market Report 2025

Description

Acute lung injury (ALI) is a serious condition marked by widespread inflammation and damage to the lungs, resulting in impaired oxygen exchange. It can be caused by direct factors such as pneumonia or trauma, or indirect causes such as sepsis or pancreatitis. Symptoms of ALI include shortness of breath, low oxygen levels, and respiratory distress.

The primary types of acute lung injury are direct injury and indirect injury. Direct injury occurs when damage happens as a direct result of an event, action, or incident. Treatment options for ALI include mechanical ventilation, pharmacotherapy, fluid management, and others. These therapies are utilized by a range of end users, such as hospitals, clinics, and other healthcare facilities.

The acute lung injury market research report is one of a series of new reports from The Business Research Company that provides acute lung injury market statistics, including acute lung injury industry global market size, regional shares, competitors with acute lung injury market share, detailed acute lung injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute lung injury industry. This acute lung injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute lung injury market size has grown steadily in recent years. It will grow from $2.48 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth during the historic period can be attributed to awareness campaigns, an increase in ICU admissions, factors such as smoking and air pollution, hospital-acquired infections, and efforts to reduce mortality rates.

The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be driven by advancements in biologics and gene therapies, government funding and grants, the development of precision medicine, regenerative medicine, stem cell therapies, and global health policy reforms. Key trends in this period include the development of biologic drugs, wearable and remote monitoring devices, inhalation-based therapies, CRISPR and gene editing technologies, and the use of biosensors for real-time analysis.

The increasing prevalence of respiratory diseases is expected to drive the growth of the acute lung injury market. Respiratory diseases encompass a range of conditions that affect the lungs and other parts of the respiratory system, leading to breathing difficulties and impaired lung function. The rising incidence of these diseases can be attributed to factors such as increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Conditions such as pneumonia can lead to acute lung injury by causing severe inflammation and damaging the alveoli, which impairs gas exchange and results in respiratory distress. For example, in September 2023, the Australian Bureau of Statistics reported a rise in the death rate from influenza and pneumonia in Australia, increasing from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, reflecting a substantial 33.54% increase. As such, the growing prevalence of respiratory diseases is fueling the expansion of the acute lung injury market.

Companies in the acute lung injury market are concentrating on developing novel treatments, such as peptide therapies, to maintain their market position. Peptide treatments involve using short chains of amino acids (peptides) as therapeutic agents for medical conditions. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based healthcare company, launched Aviptadil for treating acute respiratory distress syndrome (ARDS). This treatment offers several unique benefits, including potent vasodilatory effects that are 50 times more effective than prostacyclin, a lung protection mechanism that enhances surfactant production by binding to alveolar type II cells, anti-inflammatory properties that suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha, and immunomodulatory action to regulate immune responses in the lungs. Aviptadil has also shown clinical effectiveness in improving outcomes for patients with severe viral-related ARDS.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition strengthens Ligand's portfolio by integrating innovative therapies, particularly in immunotherapy and cancer treatment. It also expands Ligand's research and development capabilities, opening up new revenue opportunities and reinforcing its position in the biotech industry. Apeiron Biologics AG, an Austria-based biotechnology company, is actively involved in developing treatments for acute lung injury (ALI).

Major players in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., and MediciNova Inc.

North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute lung injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute lung injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute lung injury market consists of revenues earned by entities by providing services such as intensive care unit (ICU) care, mechanical ventilation, oxygen therapy, extracorporeal membrane oxygenation, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lung injury market also includes sales of mechanical ventilators, oxygen therapy products, inhaled medications, sedation and analgesics, and diuretics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Lung Injury Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute lung injury market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute lung injury ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute lung injury market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Injury Type: Direct Injury; Indirect Injury
2) By Therapy: Mechanical Ventilation; Pharmacotherapy; Fluid Management; Other Therapies
3) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury; Aspiration Pneumonitis; Pneumonia-Related Acute Lung Injury; Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury; Shock-Induced Acute Lung Injury; Acute Lung Injury Due To Blood Transfusion; Acute Lung Injury Associated With Pancreatitis
Companies Mentioned: Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Medtronic plc; Baxter International Inc.; Ono Pharmaceutical Co Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33634

1. Executive Summary

2. Acute Lung Injury Market Characteristics

3. Acute Lung Injury Market Trends And Strategies

4. Acute Lung Injury Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Lung Injury Growth Analysis And Strategic Analysis Framework

5.1. Global Acute Lung Injury PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acute Lung Injury Market Growth Rate Analysis
5.4. Global Acute Lung Injury Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acute Lung Injury Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acute Lung Injury Total Addressable Market (TAM)

6. Acute Lung Injury Market Segmentation

6.1. Global Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Injury
Indirect Injury
6.2. Global Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mechanical Ventilation
Pharmacotherapy
Fluid Management
Other Therapies
6.3. Global Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
6.4. Global Acute Lung Injury Market, Sub-Segmentation Of Direct Injury, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trauma-Induced Acute Lung Injury
Aspiration Pneumonitis
Pneumonia-Related Acute Lung Injury
Inhalation Injury
6.5. Global Acute Lung Injury Market, Sub-Segmentation Of Indirect Injury, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sepsis-Related Acute Lung Injury
Shock-Induced Acute Lung Injury
Acute Lung Injury Due To Blood Transfusion
Acute Lung Injury Associated With Pancreatitis

7. Acute Lung Injury Market Regional And Country Analysis

7.1. Global Acute Lung Injury Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acute Lung Injury Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Lung Injury Market

8.1. Asia-Pacific Acute Lung Injury Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Lung Injury Market

9.1. China Acute Lung Injury Market Overview
9.2. China Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Lung Injury Market

10.1. India Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Lung Injury Market

11.1. Japan Acute Lung Injury Market Overview
11.2. Japan Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Lung Injury Market

12.1. Australia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Lung Injury Market

13.1. Indonesia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Lung Injury Market

14.1. South Korea Acute Lung Injury Market Overview
14.2. South Korea Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Lung Injury Market

15.1. Western Europe Acute Lung Injury Market Overview
15.2. Western Europe Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Lung Injury Market

16.1. UK Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Lung Injury Market

17.1. Germany Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Lung Injury Market

18.1. France Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Lung Injury Market

19.1. Italy Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Lung Injury Market

20.1. Spain Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Lung Injury Market

21.1. Eastern Europe Acute Lung Injury Market Overview
21.2. Eastern Europe Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Lung Injury Market

22.1. Russia Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Lung Injury Market

23.1. North America Acute Lung Injury Market Overview
23.2. North America Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Lung Injury Market

24.1. USA Acute Lung Injury Market Overview
24.2. USA Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Lung Injury Market

25.1. Canada Acute Lung Injury Market Overview
25.2. Canada Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Lung Injury Market

26.1. South America Acute Lung Injury Market Overview
26.2. South America Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Lung Injury Market

27.1. Brazil Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Lung Injury Market

28.1. Middle East Acute Lung Injury Market Overview
28.2. Middle East Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Lung Injury Market

29.1. Africa Acute Lung Injury Market Overview
29.2. Africa Acute Lung Injury Market, Segmentation By Injury Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Acute Lung Injury Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Acute Lung Injury Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Lung Injury Market Competitive Landscape And Company Profiles

30.1. Acute Lung Injury Market Competitive Landscape
30.2. Acute Lung Injury Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Ono Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Lung Injury Market Other Major And Innovative Companies

31.1. Aster DM Healthcare
31.2. Octapharma AG
31.3. Cartesian Therapeutics Inc.
31.4. Vapotherm Inc.
31.5. Stemedica Cell Technologies Inc.
31.6. Implicit Bioscience Ltd.
31.7. Apeiron Biologics AG
31.8. Faron Pharmaceuticals Ltd.
31.9. Histocell Sociedad Limitada
31.10. Vasomune Therapeutics Inc
31.11. Windtree Therapeutics Inc.
31.12. Qx Therapeutics Inc.
31.13. Asklepion Pharmaceuticals LLC
31.14. ReAlta Life Sciences Inc.
31.15. MediciNova Inc.

32. Global Acute Lung Injury Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Lung Injury Market

34. Recent Developments In The Acute Lung Injury Market

35. Acute Lung Injury Market High Potential Countries, Segments and Strategies

35.1 Acute Lung Injury Market In 2029 - Countries Offering Most New Opportunities
35.2 Acute Lung Injury Market In 2029 - Segments Offering Most New Opportunities
35.3 Acute Lung Injury Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer